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Schizotypy refers to a constellation of personality traits that are believed to mirror the sub-
clinical expression of schizophrenia in the general population. Evidence from pharmacolog-
ical studies indicates that dopamine (DA) is involved in the etiology of schizophrenia. Based
on the assumption of a continuum between schizophrenia and schizotypy, researchers
have begun investigating the association between DA and schizotypy using a wide range
of methods. In this article, we review published studies on this association from the follow-
ing areas of work: (1) experimental investigations of the interactive effects of dopaminergic
challenges and schizotypy on cognition, motor control, and behavior (2), dopaminergically
supported cognitive functions (3), studies of associations between schizotypy and polymor-
phisms in genes involved in dopaminergic neurotransmission, and (4) molecular imaging
studies of the association between schizotypy and markers of the DA system. Together,
data from these lines of evidence suggest that DA is important to the expression and expe-
rience of schizotypy and associated behavioral biases. An important observation is that the
experimental designs, methods, and manipulations used in this research are highly het-
erogeneous. Future studies are required to replicate individual observations, to enlighten
the link between DA and different schizotypy dimensions (positive, negative, cognitive
disorganization), and to guide the search for solid DA-sensitive behavioral markers. Such
studies are important in order to clarify inconsistencies between studies. More work is also
needed to identify differences between dopaminergic alterations in schizotypy compared
to the dysfunctions observed in schizophrenia.
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INTRODUCTION
Schizotypy, first coined by Rado (1), is a set of personality traits
thought to mirror the subclinical expression of schizophrenia in
the general population. Schizotypy encompasses behaviors, cogni-
tions, and emotions resembling the signs and symptoms of schiz-
ophrenia. It is typically assessed in the general population using
psychometric self-report questionnaires including, among others,
the Schizotypal Personality Questionnaire (SPQ) (2), the Oxford–
Liverpool Inventory of Feelings and Experiences (O-LIFE) (3),
the Chapman scales (4), and the Rust Inventory of Schizotypal
Cognitions (RISC) (5). Factor analytic studies have shown that
schizotypy consists broadly of three subdimensions (3, 6). The
positive schizotypy dimension describes perceptual aberrations
resembling the hallucinations of schizophrenia as well as unusual
views and ideas resembling the delusions of schizophrenia. The
negative schizotypy dimension describes a loss of normal emo-
tional, physical, and social functions such as the experience of
pleasure or interest in social contacts. Finally, the disorganized
dimension encompasses eccentric behavior and odd speech. Over-
all, the symptomatic phenomenology of schizotypy thus resembles
the factor structure of symptoms reported in schizophrenia (7).
The literature tends to draw upon two scientific approaches
toward the study of schizotypy, i.e., the quasi-dimensional and
fully dimensional approaches. The quasi-dimensional, psychi-
atrically oriented approach, proposed by Meehl (8, 9), regards
schizotypy as the subclinical expression of the symptoms of schiz-
ophrenia (10, 11). In that approach, schizotypal individuals are
hypothesized to carry the genetic risk for schizophrenia. Evidence
for this approach stems from some (12), but not all (13), taxo-
metric studies. The fully dimensional approach (14), championed
by Eysenck and Claridge (13, 15–18), regards schizotypy as a per-
sonality trait which is continuously distributed. It is assumed that
schizotypal symptoms in the healthy population are qualitatively
similar though quantitatively milder than those observed in schiz-
ophrenia. Evidence for the fully dimensional approach stems from
taxometric studies that consider positive skewness of sample distri-
bution (13). The high prevalence of psychotic-like experiences in
the general population is also in accordance with the fully dimen-
sional approach (19, 20). Importantly, both approaches emphasize
the observation of variation in schizotypal features in the popu-
lation. More work is, however, needed on the exact nature of the
distribution and the boundary between non-clinical schizotypy
and clinical schizophrenia (12, 13, 21, 22).
Irrespective of these open psychometric questions, biopsycho-
logical research on schizotypy is also based on the continuum
assumption. There is considerable evidence that behavioral and
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brain correlates of schizophrenia are also related to schizotypy
[for review, see, e.g., Ref. (11, 23, 24)]. By and large, the focus of
these schizotypy studies has been on behavioral, cognitive, brain
structural, and brain functional measures. Neuronal information
transfer is, however, only possible with functional neurochem-
ical transmissions at synapses. Therefore, neurochemical studies
involving pharmacological challenges or molecular imaging meth-
ods are of utmost importance for our understanding of schizotypy.
Most prominent so far are studies that link schizotypy to dopamine
(DA). Comparable to above mentioned study domains, this link
originates in the continuum assumption because schizophrenia
has been linked to DA (25, 26), schizotypy might be associated
with DA as well. In the following, we will explore this possible
link. We will describe a selection of relevant psychopharmaco-
logical studies in patients with schizophrenia before referring to
schizotypy studies that test the possible link to DA. First, however,
we briefly introduce the structure and function of the DA system.
At this point, it should be mentioned that the schizophrenia
spectrum also of course includes individuals with schizotypal per-
sonality disorder (SPD) and those at increased genetic or clinical
risk for the illness. However, in the interest of focus, we restrict this
overview to psychometrically identified schizotypy. Of course, it
should be acknowledged that some, but not all, individuals with
high levels of schizotypy also qualify for a diagnosis of SPD. For
example, Raine (2) observed SPD in 55% of participants with SPQ
scores in the top 10% of the distribution.
THE STRUCTURE AND FUNCTION OF HUMAN DOPAMINE
SYSTEMS
Neurotransmitters exert different actions throughout the brain;
the type of action depends on the neurotransmitter, action site,
and/or neuronal circuit (27). For instance, the amino acids GABA
(inhibitory) and glutamate (excitatory) are found throughout the
brain. Acetylcholine and monoamines (DA, norepinephrine, sero-
tonin), on the other hand, are organized in systems. Systems imply
that cell bodies producing these substances are located subcorti-
cally in anatomically circumscribed regions (27). In the case of
DA, the nigrostriatal (important to motor control), mesolimbic
(important to reward and motivation), and mesocortical (impor-
tant to prefrontal functions) pathways have been distinguished
on the basis of where their cell bodies are located and where
their axons project. Moreover, two major DA receptor families
have been identified, viz. the D1-like (D1 and D5) and D2-like
(D2, D3, D4) receptors that are widely distributed throughout the
brain. Because of the importance of the DA system to various
mental health conditions, its complexity and functioning remain
intensively investigated (28).
Of course, complex mental health disorders cannot be
explained by single changes to complex neurotransmitter sys-
tems. Instead, subsystems are likely contributors to different psy-
chopathologies. DA has indeed been associated with diverse neu-
rological and psychiatric conditions such as Parkinson’s disease,
schizophrenia, addiction, and attention deficit hyperactivity dis-
order [e.g., Ref. (29, 30)]. Also, neurotransmitter systems are not
modular, i.e., they do not exert their actions in isolation. A given
neurotransmitter system is in constant interaction with other sys-
tems. In schizophrenia, interactions between the DA and glutamate
systems are intensively debated (31). Accordingly, pharmacologi-
cal compounds can enhance DA release while also enhancing the
release of the other two monoamines (norepinephrine, serotonin).
The latter release might happen directly or indirectly through
metabolism of DA into norepinephrine and the latter into sero-
tonin (32,33). This overall complexity in neurotransmitter systems
highlights the fact that individual psychopharmacological stud-
ies have inherent limitations in investigating the link between
schizotypy and DA. As exemplified in the following sections, we
depend on findings from a multitude of studies using different but
complementary approaches.
DOPAMINERGIC EFFECTS IN PATIENTS WITH
SCHIZOPHRENIA
Neuroleptics were first discovered in the early 1950s (34). Since
their discovery, it has been shown that these DA antagonists ame-
liorate acute psychotic symptoms [e.g., Ref. (35, 36)]. It is still
accepted that DA is key in the treatment and pathophysiology of
schizophrenia (37–39). For example, patients with schizophrenia
profit from DA antagonistic treatment (38) and show symp-
tom worsening after DA agonistic treatment (40, 41). In healthy
populations, DA agonists can trigger psychotic or psychosis-like
symptoms (42, 43). Such findings led to the suggestion that a
hyperactive DA system results in acute psychotic symptoms (25,
38). Davis et al. (25) further elaborated on this suggestion by
proposing DA abnormalities to depend on the brain region, i.e.,
D1 receptors being predominantly found cortically and D2 recep-
tors subcortically. They specified that frontal hypodopaminergia
would result in striatal hyperdopaminergia. Regarding symptoms,
they related negative symptoms to frontal hypodopaminergia and
positive symptoms to striatal hyperdopaminergia.
Howes and Kapur (44) refined this previous DA theory by
suggesting that multiple “hits” (e.g., social, environmental, and
cultural stressors) result in DA dysregulation at the pre-synaptic
level. Such DA dysregulation is hypothesized to lead to changes in
how events are appraised,potentially because events become overly
salient (i.e., attract increased allocation of meaning). According
to these authors, an alteration in pre-synaptic DA is the final
common pathway to psychosis and psychosis-proneness (45). Yet,
other evidence points to the role of post-synaptic processes (46).
Very recently, Seeman (39) outlined how dynamic changes of post-
synaptic D2 receptors might contribute to symptoms experienced
in schizophrenia. Mainly based on animal studies, Seeman reports
on D2 receptors that can either take a high affinity state for DA
(D2High) or a low affinity state for DA (D2Low). Reviewing the
literature, he suggests that psychosis is associated with the more
active and normally less common D2High state.
Overall,despite various suggestions on the involvement of alter-
native neurotransmitter systems in psychosis and, by inference,
schizophrenia (31, 47), recent notions highlight that DA is the
likely final common pathway to psychosis. The precise mech-
anisms and sites of action remain inconclusive, and continued
research reveals ever more complex synaptic dynamics such as
the ones described for the D2High and D2Low affinity states.
It remains to be clarified whether such alterations of the DA
system are specific to overt clinical psychosis or are also evi-
dent, though less pronounced, along the schizophrenia spectrum
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including healthy schizotypy. Howes and Kapur (44) previously
reviewed a number of studies showing an involvement of DA in
the prodromal state, in ultra-high risk populations, in relatives of
schizophrenia patients and in schizotypy. Because these popula-
tions lie on the psychosis continuum, part of these and additional
studies will be discussed in more detail.
In an 18F-dopa positron emission tomography (PET) study,
Howes et al. (48) observed that patients with prodromal psychotic
symptoms showed enhanced striatal 18F-dopa uptake, interme-
diate to that of patients with schizophrenia and healthy controls.
This enhanced uptake correlated positively with prodromal symp-
tomatology and neuropsychological impairments [but see in Ref.
(49)]. In a 3-year follow-up study, Howes et al. (50) observed
that greater striatal DA synthesis capacity was observed in a psy-
chosis transition group as compared to a group that did not transit
into psychosis. Moreover, this capacity in the transition group
correlated positively with symptom severity. In another study,
elevated pre-synaptic striatal uptake was comparable between
patients with SPD and remitted patients with schizophrenia (51).
It was also elevated for individuals at ultra-high risk for psychosis,
i.e., those who show impaired socio-occupational functions and
attenuated psychotic symptoms (e.g., perceptual abnormalities,
paranoia) (52). An increase of striatal pre-synaptic DA synthe-
sis has also been observed in first-degree relatives of patients
with schizophrenia (53). Relatives additionally showed an altered
stress response, demonstrated by increased levels of plasma DA
metabolites when compared to healthy controls (54). This increase
was associated with psychotic-like symptoms subsequent to daily
stressors (experience sampling methodology) (55). In yet another
study, psychotic patients and unaffected relatives released signif-
icantly more DA in striatal regions subsequent to the inhalation
of delta-9-tetrahydrocannabinol (the main psychoactive ingredi-
ent of cannabis) than healthy controls (56). In sum, these studies
show that DA abnormalities are not restricted to individuals with
a clinical diagnosis of schizophrenia, but are also evident in the
extended phenotype. Findings specific to schizotypy are presented
further below.
METHODS IN THE STUDY OF DOPAMINE AND ITS RELATION
TO SCHIZOTYPY AND COGNITION
Various methods are available to measure aspects of the DA system
in healthy humans. The most promising to study the link between
schizotypy and DA include (1) experimental pharmacological
challenges of the DA system, (2) neurobiologically informed, DA-
sensitive cognitive and behavioral measures, (3) molecular studies
of genes involved in DA neurotransmission, and (4) molecular
neuroimaging of the DA system. Here, we briefly outline these
methods. In the next section, we discuss how they have been used
in work on schizotypy.
The first methodological approach directly tests the link
between schizotypy and DA. For instance, one could test DA
agonistic and antagonistic treatment effects on the experience of
schizotypy as well as related correlates in healthy populations. This
approach corresponds to tests of medication effects in patients.
In patients, however, pharmacological treatment consists of the
daily administration of medication over many weeks, given that
the clinical antipsychotic effects of such compounds take several
weeks to emerge (57). When testing healthy populations, such
long-term drug administration would be unethical and potentially
dangerous. For instance, antipsychotic treatment causes severe
side effects [e.g., Ref. (58) for a meta-analysis]. These and other
(e.g., economic and clinical) factors explain why the investiga-
tion of long-term medication effects is common in clinical studies
while single (or limited) short-term drug effects are frequently
investigated in healthy volunteers.
Importantly, short-term dopaminergic drug applications
directly modulate the DA system, thereby allowing the evalua-
tion of dopaminergic effects on domains of cognition, emotion,
motor control and their neural correlates. Such studies tend to take
place in well-controlled laboratory settings using tight method-
ological controls, such as double-blind procedures and placebo
conditions [e.g., Ref. (59–61)]. Such paradigms inform on acute
drug effects and their interaction with schizotypy. They also allow
addressing clinical questions hard to implement in patients (40–
43). As outlined above, however, it should be borne in mind that
the DA system does not work in isolation but instead interacts
with other neurotransmitter systems; therefore, the specificity of
any pharmacological effect on behavior and cognition remains to
be characterized further.
The second methodological approach involves the assessment
of DA-mediated cognitive and behavioral performance measures
and their covariance with schizotypal personality traits. This
approach is indirect in comparison to the first approach. Yet, the
use of DA-mediated performance measures is popular. Various
paradigms have been drawn upon (62–67). Of importance, pre-
vious studies have shown that these performance measures are
sensitive to modulations of the DA system. In particular, such mea-
sures are affected by dopaminergic drugs in humans [e.g., Ref. (61,
68, 69)], human mental health conditions in which the DA system
is affected [e.g., Ref. (64, 65)] and by experimental dopaminergic
interventions in animals [e.g., Ref. (64, 69)].
The third methodological approach involves molecular imag-
ing methods. As indicated above, methods such as PET and single
photon emission computed tomography (SPECT) can provide
in vivo data on markers of the DA system (such as DA synthesis
or receptor and transporter availability) in the human brain (45).
These markers can be quantified and related directly to schizo-
typy scores. As will be detailed below, PET and SPECT methods
have recently been applied to study the DA system as a function of
schizotypy.
The fourth methodological approach involves the exploration
of the role of DA in schizotypy by studying statistical associa-
tions of schizotypy scores with variants in genes whose protein
products are known to be involved in the DA system (70, 71).
Such genes may include those coding for receptors, transporters
or enzymes involved in DA synthesis, release, reuptake, degrada-
tion or any other aspect of DA transmission. The effects on DA
transmission of such genetic variants, when known, allow draw-
ing conclusions about differences in DA transmission in relation
to individual differences in schizotypy.
DOPAMINE AND SCHIZOTYPY: EMPIRICAL EVIDENCE
A role of DA in schizophrenia and schizotypy has long been
postulated (67, 72–74). Empirical evidence on the nature of the
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association between DA and schizotypy has been scarce and the
association has rarely been investigated directly (68, 75). However,
studies have accumulated over the last 15 years. Here, we give an
overview on the outcome of these studies, irrespective of which
methodological approach has been applied. In case that DA was
investigated indirectly (the second methodological approach men-
tioned above), we distinguish between studies that assessed more
basic behavioral functions and those that assessed higher cogni-
tive functions. Often these studies added a direct manipulation
of the DA system using the first methodological approach out-
lined above. Therefore, we discuss these together with the purely
behavioral data on simple or complex behavioral functions. In the
case of molecular genetic and molecular imaging studies, many
findings are based on associations with questionnaire scores. We
discuss these studies separately.
BASIC BEHAVIORAL FUNCTIONS
Turning behavior is a behavioral marker of a relatively hyper-
active DA system in one over the other hemisphere. Animal
studies [Ref. (76) for overview] and a study testing patients with
asymmetrical Parkinson’s disease (77) showed that whole-body
turning occurs away from the hemisphere with the more active
DA system. Acutely psychotic patients (65) and individuals with
elevated positive schizotypal features (74) yielded a preference
for left- over right-sided turns pointing to a relative hyperactive
right-hemispheric DA system along the schizophrenia spectrum.
In a study that directly tested the influence of DA on turning
behavior, half of the participants received a placebo and the
other half a non-specific DA agonist (levodopa) (78). Turning
biases were investigated as a function of participants’ positive
and negative schizotypal features. The authors found that ele-
vated positive schizotypy associated with a left- over right-sided
turning preference in the placebo group. In this same group, neg-
ative schizotypy associated with a right- over left-sided turning
preference. In the levodopa group, these relationships were not
strengthened, but actually reversed. The authors argued that a
higher than normal DA availability might have balanced out pre-
existing DA asymmetries. In another experiment on the same
participants, schizotypy and levodopa treatments were unrelated
to lateral turning biases in a computer-based object-rotation
task (66).
Spontaneous eye blink rate (SBR) is indicative of cerebral DA
activity. Eye blinks occur spontaneously, frequently, and mostly
without awareness. They are primarily important for the health
of the eye surface and clarity of vision. Decades ago, SBR has
been suggested to be a sensitive marker of striatal DA activity
(64). SBR has been associated with changes in concurrent cog-
nitive processes, perceptual load, and level of arousal (79, 80). It
is enhanced in schizophrenia, in particular in the unmedicated
or drug-naïve state (64, 81, 82), and decreases with antipsychotic
treatment (64,82,83). In line with Davis et al.’s (25) notion of a link
between negative symptoms and hypodopaminergia on the one
hand and positive symptoms and hyperdopaminergia on the other
hand, negative symptoms were associated with a decreased SBR
(83) and positive symptoms with an increased SBR (82, 83). Addi-
tionally, SBR increased with a DA agonistic treatment in healthy
individuals (84, 85).
In a dopaminergic challenge study, half of the participants
received a placebo while the others received an unspecific DA
agonist (levodopa) (86). SBR did not differ between substance
groups, but correlated positively with negative (but not positive)
schizotypy scores after levodopa intake. The authors conjectured
that this effect occurred because negative schizotypy is a priori
related to hypodopaminergia. In another study, however, SBR
correlated positively with participants’ psychoticism scores, a sub-
dimension of the Eysenck Personality Questionnaire (87). Some
authors argued that psychoticism forms part of the schizotypy
spectrum (88). Other authors linked psychoticism to impulsive-
ness, lack of cooperation, rigidity, low superego control, low social
sensitivity, low persistence, lack of anxiety, and lack of feelings of
inferiority (89) – features associated with borderline and anti-
social personality disorder rather than with the schizophrenia
spectrum (90, 91). The psychoticism dimension seems indeed the
least clear-cut dimension of the three Eysenckian dimensions (90,
91). Whatever the psychoticism dimension is measuring, the latter
SBR finding suggests that psychoticism is probably more sensitive
to the DA system subserving SBR than is schizotypy (or negative
schizotypy) as such.
Stereotyped behavior is thought to be sensitive to DA. It is
observable in schizophrenia (92, 93) and after amphetamine con-
sumption in healthy individuals (69). In schizophrenia, stereo-
typed behavior occurs on the motor (e.g., walking backwards and
forwards, repetitive jaw movements) (94) and higher cognitive
level. For instance, perseverative errors in the Wisconsin Card
Sorting Test are elevated in schizophrenia [Ref. (95) for overview],
SPD (96, 97) and as a function of both high positive and negative
schizotypy (98, 99). Random number generation tasks show that
patients with schizophrenia (100, 101), healthy participants after
amphetamine administration (69), and healthy positive schizo-
typal participants (102, 103) yield stereotypical response biases
when compared to respective controls. Finally, when rotating
figures into advantageous target positions on a computer screen,
left or right turns had to be applied dynamically to obtain maximal
scores (66). Sticking stereotypically to one or the other direc-
tion would be disadvantageous. The latter study reported on two
experiments with one being a between-subject levodopa placebo-
controlled experiment. The authors observed that individuals with
relatively high as compared to low positive schizotypy were behav-
ing more stereotypically. Yet, in the levodopa group, high positive
schizotypal individuals performed less stereotypically than the low
positive schizotypal individuals. Comparable to the findings on
turning behavior, results seem to suggest that a higher than normal
DA availability in positive schizotypes balances out pre-existing
DA-mediated behavioral abnormalities.
Prepulse inhibition (PPI) is another DA-sensitive measure
that has been studied in relation to schizotypy. PPI is a cross-
species phenomenon that refers to a reduction in the amplitude
of the startle response to a strong sensory stimulus, the pulse,
if this stimulus is preceded by 30–500 ms by a weak stimulus,
the prepulse (104). The weak prestimulus is thought to evoke
inhibitory mechanisms, which limit further stimulation until the
processing of the prepulse has been completed, resulting in a
reduced impact of the pulse. PPI is thought to reflect an early
sensory gating process to avoid interference from simultaneous
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processing of several stimuli. It is, thus, a largely automatic mea-
sure of inhibitory function. Experimental studies in animals have
shown that a cortico-striato-pallido-thalamic circuitry underlies
PPI (105).
Patients with schizophrenia (106) and SPD (107) show repro-
ducible reductions in the magnitude of PPI, which is thought to
lead to sensory overstimulation causing cognitive and behavioral
confusion. Also, PPI deficits are induced in numerous experimen-
tal models of schizophrenia through, e.g., isolation rearing (108),
ketamine (109), sleep deprivation (110, 111), and phencyclidine
(112). The robust and reliable PPI reduction in schizophrenia
can be restored, at least partially, with antipsychotic treatment,
with some advantage of atypical compounds over first-generation,
typical antipsychotics (113–119).
Importantly, reduced PPI has been observed in relation to ele-
vated SPQ total, cognitive-perceptual and interpersonal scores
(120), Minnesota Multiphasic Personality Inventory (MMPI)
psychosis-proneness scores (121) and Eysenckian psychoticism
scores (122). Evidence from a functional magnetic resonance
imaging (fMRI) study of PPI points to reduced activation in the
insula, putamen, thalamus, inferior parietal cortex, hippocampal
gyrus, and fusiform gyrus in relation to higher levels of Eysenck-
ian psychoticism scores (122). These BOLD patterns show some
resemblance with the data obtained from samples of patients with
schizophrenia (123). Of relevance to the present discussion, areas
such as the putamen are rich in DA receptors, consistent with the
hypothesis that PPI is at least in part dopaminergically mediated
(124–126).
A final basic DA-mediated paradigm is latent inhibition (LI)
(62, 127, 128). Comparable to PPI, LI is a cross-species phenom-
enon, which is sensitive to pro- and antidopaminergic challenges
(62). LI refers to the finding that non-reinforced pre-exposure to
a stimulus, that is later to be conditioned, causes less efficient con-
ditioning when the same stimulus is subsequently reinforced. This
phenomenon has been observed in both humans and animals. LI
has also been investigated in relation to schizophrenia and schizo-
typy. A recent review showed reduced LI in the acute phase of
patients with schizophrenia and preserved LI in chronic schiz-
ophrenia (129). That review also found a modest but relatively
consistent relationship between schizotypy and LI, particularly
of positive schizotypy (130). In particular, higher levels of pos-
itive schizotypy seem to be associated with less LI in healthy
participants. These studies, together, suggest an involvement of
dopaminergic alterations in the LI deficits in schizophrenia and
positive schizotypy.
HIGHER COGNITIVE FUNCTIONS
Dopamine is thought to modulate the signal-to-noise ratio in
semantic networks (131, 132). The reduction of prefrontal tonic
dopaminergic modulation (hypofrontality) in schizophrenia is
assumed to decrease the contrast between a signal and noise.
This decreased contrast leads to a disinhibited spreading activa-
tion within semantic networks [see in Ref. (132) for an overview].
This increased spreading activation would result in remote asso-
ciations (psychotic symptom) and enhanced semantic priming
effects (laboratory measures) in schizophrenia (132). In healthy
populations, on the other hand, an experimentally enhanced DA
availability (levodopa consumption) focused such priming effects
(133). Yet, this dopaminergic modulation of semantic networks
differed for the two cerebral hemispheres with a hyperdopamin-
ergia being more prominent in the right than left hemisphere (see
previous section). This hyperdopaminergia (potentially result-
ing from a frontal hypodopaminergia) has been considered to
explain the observation that enhanced spreading activation was
more relevant for the right than left hemisphere in schizophre-
nia (134) and healthy individuals high in positive schizotypy (60,
135). Independent studies suggested that these DA-mediated func-
tions explain both these lateralized priming effects and enhanced
remote associative processing more generally (136, 137) as well as
right-hemisphere shifts of functions in a broader sense. Indeed,
the left hemisphere seems compromised in patients with schizo-
phrenia with DA antagonists restoring if not reversing such altered
hemispheric asymmetries (138–143).
Studies showed that lateralized lexical decision performance is
relatively biased toward the right hemisphere in high as compared
to low scorers on a positive but not negative schizotypy question-
naire (144, 145). In a pharmacological challenge study, superior
left hemisphere language dominance was associated with elevated
negative schizotypy scores in a levodopa (but not placebo) group
(145). Thus, levodopa might restore left hemisphere language
dominance in healthy individuals through (i) the attenuation of
the contribution of the right hemisphere to language as a func-
tion of positive schizotypy and (ii) an increased contribution of
the left hemisphere as a function of negative schizotypy. In an
independent sample, but using the same task, the authors cal-
culated signal detection theory measures of sensitivity (d-prime)
and response tendency (criterion) (146). Results showed lower d-
prime in the levodopa than in the placebo group in individuals low
in positive schizotypy. For the response criterion, individuals in the
placebo group showed a loosened versus conservative response cri-
terion when being high versus low in positive schizotypy. In the
levodopa group, these response tendencies were attenuated. This
study suggests that a higher than normal DA availability (i) reduces
d-prime in low positive schizotypy individuals and (ii) turns low
positive schizotypy individuals less conservative and high posi-
tive schizotypy individuals more conservative in their response
behavior.
Higher cognitive functions such as working memory and cog-
nitive control have also been studied using experimental psy-
chopharmacological designs. Using a between-subjects, double-
blind, placebo-controlled design with groups of high and medium
total SPQ scores, amisulpride, a clinically effective antipsychotic
with strong D2/D3 receptor antagonistic action, improved work-
ing memory and verbal fluency performance in the schizotypy
group but impaired it in the medium schizotypy control group
(59). The same multi-center study investigated the effects of
risperidone, a clinically effective atypical antipsychotic with action
on D2 as well as 5-HT receptors, on performance on the antisac-
cade task, a prominent measure of response inhibition (147, 148).
It was found that risperidone impaired antisaccade performance
in the medium schizotypy group, whereas performance in the
high schizotypy group showed a non-significant tendency toward
improvement (149). These findings are in agreement with previ-
ous evidence of risperidone impairing antisaccade performance
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in healthy controls (150) but improving it in patients with
schizophrenia (151, 152).
To summarize, findings of this section suggest that individuals
with high levels of schizotypy may benefit from DA agonists in
terms of cognitive performance. In contrast, individuals with low
levels of schizotypy may deteriorate in cognition with DA agonists.
Concerning DA antagonists, people with high levels of (particu-
larly positive) schizotypy may benefit in cognitive function from
DA antagonistic compounds similar to patients with schizophre-
nia, or at least tolerate them. People with low or medium levels in
(particularly positive) schizotypy may become impaired in these
functions. Overall, given the role of DA in the effects of clinically
effective antipsychotics (153), the presented data indicate that DA
impacts some of the cognitive deficits observed in high (mainly
positive) schizotypy (24, 78, 154). However, antipsychotics such as
risperidone do not act only on the DA system, thereby limiting the
implications for a dopaminergic basis of schizotypy (149).
SCHIZOTYPY AND DOPAMINE SYSTEM GENES
Twin studies have established that individual differences in the var-
ious subdimensions of schizotypy in the general population are to
a significant part explained by additive genetic factors. Heritability
estimates are in the range of 30–50% [see, e.g., Ref. (155–157)],
although not all studies have found significant heritabilities (158).
These behavioral genetic studies, thus, provide a basis for mol-
ecular genetic investigations such as those specifically targeting
candidate genes related to the DA system.
The most frequently studied gene in the context of schizotypy
is the gene coding for catechol-O-methyltransferase, the COMT
gene (159–161). These studies were originally informed by sig-
nificant associations of a single nucleotide polymorphism (SNP)
in the COMT gene with schizophrenia (162); however, later meta-
analyses have suggested that this association is not significant (163,
164). The COMT enzyme degrades catecholamines including DA
in the synaptic cleft. Due to the paucity of the DA transporter in
the prefrontal cortex, COMT plays a particularly prominent role
in degrading pre-synaptic DA in that part of the brain. TheCOMT
gene (located in chromosome 22q11.1-q11.2) contains a G to A
missense mutation, resulting in a substitution of methionine (met)
for valine (val) at codon 158 of the membrane-bound isoform of
the protein (reference sequence identification code rs4680). This
allelic variation (val158met) is a functional polymorphism: The
met158 allele has about one third to one fourth of the activity of the
val158 allele, resulting in less efficient catecholamine catabolism
and, therefore, higher DA levels.
A number of published studies have reported associations
between schizotypy and the COMT val158met polymorphism in
healthy subjects. A series of publications from a large-scale study
of apparently healthy young men, the ASPIS study, has provided
evidence that the high-activity Val allele may be associated with
schizotypy. In particular, the Val allele was found to be associated
with elevated total SPQ and Perceptual Aberration Scale scores in
a first analysis of 379 subjects (165). In a subsequent study using
an extended sample of 543 individuals and a factor analysis of SPQ
into four factors (cognitive-perceptual, negative, disorganization
and paranoia) the Val loading was associated with increased total
SPQ and increased negative and disorganized factor scores (71).
In a further extension of 908 subjects where the analysis was also
performed for individual SPQ dimensions, an association of Val
with increased total SPQ, negative disorganized, and paranoia fac-
tors was observed. Additionally, there were specific relations of
Val loading with increased scores in magical thinking, constricted
affect, and odd speech subscales of the SPQ (166).
Broadly confirming this evidence, Grant et al. (167) observed
in an independent sample of 280 healthy volunteers that Val/Val
homozygotes had significantly higher positive schizotypy scores
(O-LIFE unusual experiences) than Met carriers.
Other studies obtained evidence of an association between the
Val allele and increased schizotypy in samples of relatives of psychi-
atric patients. One study (168) observed that among 81 first-degree
relatives of schizophrenia patients the Val allele was associated with
high negative schizotypy (social and physical anhedonia), while
no association was found in 38 relatives of patients with bipolar
disorder or in 30 healthy controls. Schürhoff et al. (70) studied
COMT rs4680 and schizotypy in a combined sample of relatives
of schizophrenic patients, relatives of bipolar patients and healthy
controls (total N = 106). The authors observed higher total, posi-
tive and negative SPQ schizotypy (but not disorganization) scores
in association with an increasing number of Val alleles.
Overall, these studies suggest that theVal allele is associated with
higher levels of various schizotypy subdimensions. However, evi-
dence to the contrary as well as failures to replicate have also been
published. For example, Sheldrick and colleagues (169) reported
higher SPQ-B Disorganization scores in the COMT Met/Met
group than in the Val/Val group (N = 522 volunteers). Also, no sig-
nificant association of overall schizotypy with rs4680 genotype was
observed in individuals with velo-cardio-facial syndrome (170) or
in a mixed sample of members from families with bipolar disorder
as well as unaffected controls (total N = 222) (171). Ma and col-
leagues (172) similarly reported a lack of significant associations
between rs4680 and SPQ total and subscale scores in 465 Chinese
participants. Finally, Ettinger et al. (173) found no statistically sig-
nificant association of positive schizotypy (RISC) with rs4680 in a
small sample of healthy males (N = 31).
These inconsistencies remain to be resolved, both through addi-
tional original studies and a comprehensive meta-analysis that
also addresses potential moderator variables. A number of factors
may play a role, including the choice of schizotypy questionnaire
(174) as well as the ethnic and sociodemographic composition
of the sample (175). Other moderating variables may also be
important. For example, the above mentioned study by Savitz and
colleagues (171) observed, in the absence of an overall associa-
tion of rs4680 with STA schizotypy, that there was an interaction
between childhood trauma (as measured with the Childhood
Trauma Questionnaire) and rs4680 on STA: The genotype was
associated with STA only in individuals with higher trauma scores,
such that Val/Val individuals showed increasing STA with increas-
ing trauma,whereas other genotype groups did not. The possibility
of interactive effects of genes and the environment is intriguing
and needs to be examined in more detail.
In addition to COMT, a number of other DA-related genes
have been investigated in relation to schizotypy. Ettinger et al.
(173) obtained no evidence of significant associations of posi-
tive schizotypy (RISC) with polymorphisms in the DRD3, DRD4,
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and SLC6A3 genes in a sample of 31 healthy subjects. Grant et al.
(167), however, reported significant associations of different O-
LIFE subscales with DRD2 Taq1A, MAOA-uVNTR and SLC6A3
in 288 participants. Finally, a recent study by Taurisano et al.
(176) observed an association between SPQ total score and DRD2
rs1076560 in 67 subjects, with GT heterozygotes showing higher
scores than G allele homozygotes.
Overall, the discussed molecular genetic findings are promis-
ing but must be considered preliminary; they require replication
and further investigation in larger samples. Genetic research has
the possibility of informing the molecular basis of inter-individual
variation in schizotypy and as such makes a unique, non-invasive
contribution to the neuroscientific method arsenal available to
schizotypy researchers. An additional appeal of this method is
the possibility of combining genetic data with other neuroscience
methods, such as functional and structural neuroimaging (177).
MOLECULAR IMAGING OF THE DOPAMINE SYSTEM IN RELATION TO
SCHIZOTYPY
Measures of the DA system in humans can also be obtained in vivo
using molecular imaging techniques such as PET and SPECT.
These methods have been applied successfully to the study of
the dopaminergic basis of schizophrenia (45). In contrast, rela-
tively few PET or SPECT studies have investigated the relationship
between DA system markers and schizotypy.
An early 123I-IBZM single photon emission tomography inves-
tigation (178) reported a significant negative relationship between
Eysenckian psychoticism scores and D2 receptor binding in the
basal ganglia (relative to frontal cortex) in a small sample of
healthy volunteers. Extending this first evidence, a [11C]raclopride
PET study (179) found lower D2 receptor density in putamen to
be associated with higher scores on the Karolinska Scales of Per-
sonality detachment scale, a measure tapping aspects of negative
schizotypy. Breier and colleagues replicated this finding, reporting
a negative association between the Karolinska detachment scale
and striatal D2 receptor binding using [11C]raclopride PET in an
independent sample of healthy volunteers (180).
In contrast, a more recent SPECT study observed a positive
relationship between the disorganization score of the SPQ and
D2/3 receptor binding in the right striatum (relative to occipital
cortex) (181). Most recently, Taurisano et al. (176) used SPECT
and found a positive correlation between D2 receptor binding in
the right putamen and total SPQ score in individuals heterozygous
for the DRD2 rs1076560 genotype but not in individuals homozy-
gous for the G allele, suggesting interactive effects of genotype and
D2 availability on schizotypal personality. No association between
whole striatum DA synthesis capacity and total SPQ score was
observed in a PET study of subjects with persistent auditory verbal
hallucinations (182).
A different line of molecular imaging studies has focused on
dopaminergic challenges in relation to schizotypy. It has previously
been shown that patients with schizophrenia, both in the acute
phase and in remission, exhibit amphetamine-induced reductions
in D2 and D3 DA receptor binding potential in the striatum (40,
183). This result suggests increased striatal DA release in schizo-
phrenia and complements the evidence of heightened pre-synaptic
DA function in this disorder (45). Interestingly, a similar pattern
of increased striatal amphetamine-induced DA release has been
observed in SPD (51). Further evidence confirming and extend-
ing this pattern across the schizophrenia spectrum comes from
a [18F]fallypride PET study (184). That study showed significant
correlations between striatal DA release after a single administra-
tion of amphetamine and SPQ total and disorganized dimension
scores in healthy volunteers (184). Together, these studies provide
evidence for a common striatal dopaminergic dysregulation in
both schizotypy and schizophrenia.
Finally, based on evidence of stress as a possible risk factor
for schizophrenia (185), molecular imaging methods have been
employed to investigate the effects of experimentally induced stress
on DA turnover as a function of schizotypy. Using [11C]raclopride
PET, it was shown that participants with high levels of negative
schizotypy – but not controls or participants with high levels of
positive schizotypy – showed a significant stress-induced striatal
reduction in binding potential (186).
Overall, studies using molecular imaging methods such as PET
or SPECT are able to provide relatively direct markers of the DA
system in vivo and, as such, can be used profitably to investigate
its relationship not only to schizophrenia but also to schizotypy.
However, evidence of associations between DA markers and levels
of schizotypy in healthy participants is still scarce. To summarize,
while there are associations between lower D2 receptor avail-
ability and higher psychoticism and detachment, there is also a
report of an association between lower D2/3 receptor binding and
lower disorganized dimension schizotypy. This pattern may imply
differential associations of DA levels with different dimensions
of schizotypy. Finally, there is evidence of increased striatal DA
release following amphetamine administration or stress induction
in schizotypy.
CONCLUSIONS
In this overview, we discussed studies linking DA and schizo-
typy. We first introduced the neurotransmitter DA and sketched
some in vivo methods of its study in patients with schizophrenia
and healthy controls. We presented evidence from the behavioral
literature showing that high levels of schizotypy (in particular pos-
itive schizotypy) are associated with DA-sensitive functions, in line
with behavioral tendencies previously reported in schizophrenia.
In addition, we presented evidence that both increased (DA ago-
nists) and decreased (DA antagonists) DA availability seems to
be beneficial to behavioral deficits in high schizotypes (mainly
positive schizotypy). Those low in schizotypy, however, seemed
to deteriorate in their behavioral performance following antipsy-
chotic treatment. While only a careful conjecture, it seems that
an increase as well as a decrease of DA may restore function in
high schizotypes but deteriorate it in low schizotypes. Overall, we
conclude that variance in schizotypy may be explained in part by
alterations to the DA system. Of course, as noted, the DA system
does not act in isolation but in constant and complex interactions
with other neurotransmitter systems.
An underdeveloped theoretical point not only here, but also
in schizotypy research more generally, is a well-recognized frame-
work integrating empirical evidence on links between DA and
schizotypy from various levels of analysis (not only concerning
DA) into a coherent theory. Important theoretical contributions
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by Meehl (8, 9) and others (16, 187) have influenced our current
thinking on schizotypy. A significant body of new data has been
amassed that needs to be theoretically linked. In particular, we
think of the psychopharmacological, imaging and genetic findings
that are based on techniques that had not been available before.
To achieve this aim, it may be instructive to turn in two direc-
tions for inspiration, viz. in the direction of (i) personality theory
in individual differences research and (ii) clinical schizophrenia
research.
Regarding individual differences, DeYoung (188) recently inte-
grated previous assumptions into a theoretical framework that is
relevant to our discussion of the role of DA in schizotypy. Par-
ticularly relevant is his discussion of “apophenia,” i.e., individuals’
tendency for overinclusive thinking and perception. Conrad (189)
termed apophenia as the “unmotivated seeing of connections”
accompanied by a “specific experience of an abnormal meaning-
fulness” (p. 46). For instance, one can refer to apophenia when
individuals see and create pattern in random noise, whether this
noise is perceptual (190, 191), semantic (136), or probabilistic
(192). The suggestion of a link between apophenia and positive
schizotypy in particular (136, 193) including its modulation by
DA (60, 194) is not new. However, DeYoung (188) links apophe-
nia not only with positive schizotypy and the positive symptoms of
psychosis but adds another link, namely that apophenia can be pre-
dicted by openness, one of the personality traits of the five factor
model of personality (195). Accordingly, apophenia can be called
“openness to implausible patterns” [Ref. (188); p. 13]. This open-
ness and its link to apophenia are hypothesized to stem from high-
activity levels in the dopaminergic salience system. As mentioned
above (44), recent theories on the role of DA in schizophrenia
suggest that stressors dysregulate DA at the pre-synaptic control
level. This is hypothesized to lead to changes in the appraisal of
events, making them more salient (i.e., causing apophenia). Thus,
DeYoung’s (188) DA theory of personality is of interest as it ties
schizotypy in with other personality traits and establishes par-
allels with schizophrenia at the cognitive (overinclusive pattern
detection) and neurophysiological (DA) level.
These parallels link directly to the second direction of inspira-
tion, i.e., clinical schizophrenia research. Here, aberrant salience
has become a predominant topic. Current theorizing has provided
promising explanations as to how DA links with the sympto-
matic expression of the clinical condition (153, 196). Specifically,
these theories start to fill the explanatory gap between an appar-
ent neurochemical disturbance in the brain and the formation
of complex delusions and hallucinations. The argument is that
delusions arise as a result of individuals’ explanations of experi-
enced aberrant salience. This argument is based on the role of
DA in mediating both the presence or absence of reward and
the salience, such as novelty, of stimuli. Increased DA neuro-
transmission is thought to lead to aberrant salience, that is, the
direction of attention to objectively irrelevant internal or exter-
nal stimuli. Delusions are by this account thought to arise through
individuals’attempts to explain this distressing experience, likely in
interaction with prior experiences and beliefs, both personal and
socio-cultural. While it is not clear yet which aspect of salience
is particularly disturbed in schizophrenia, this work provides a
promising model for understanding an important symptom of
schizophrenia. Additionally, it remains unclear from this work
how other symptoms of schizophrenia, such as hallucinations,
thought disorder and negative symptoms arise. Because we know
of numerous established similarities between high schizotypy and
schizophrenia [see in Ref. (24) for a recent overview], such theo-
ries may be drawn upon for our understanding of schizotypy as
well.
In sum, we conclude that there is some evidence of an associ-
ation between altered DA neurotransmission and schizotypy, par-
ticularly positive schizotypy. Such work informs not only neurobi-
ological, but also cognitive models of the schizophrenia spectrum
(196) and potential neuropharmacological treatments (197).
FUTURE WORK
The current overview illustrates the numerous and varied ways
in which researchers have aimed to investigate the link between
schizotypy and DA. The heterogeneity in the approaches and the
sometimes conflicting results make it difficult to arrive at a clear-
cut conclusion. Most of the time, we cannot directly compare
results across study domains. This heterogeneity is of course frus-
trating but may also be constructive in providing directions as to
where more work needs to be done.
Specific suggestions for future work include (1) the need to
continue working on the development of an overarching theory
of schizotypy (2), the assessment of the direction of effects of
increasing and decreasing DA availability in high and low schizo-
typy of different dimensions (3), the role of concomitant illegal
and legal drug use (4), the role of individuals’ genetic makeup, and
(5) the identification of schizotypal markers that are truly unfa-
vorable concerning high-risk states and those that are potentially
of little psychopathological impact.
In our view, the field needs both carefully controlled labora-
tory experiments and studies that account for the spontaneous
self-administration of psychoactive ingredients that frequently act
on the DA system. For instance, there is insufficient knowledge
as to why schizotypal individuals and patients with schizophrenia
consume DA-sensitive drugs to a higher degree than controls (198–
200). It remains to be investigated whether this drug consumption
is a potential trigger for psychosis or whether such individuals
medicate themselves by altering their DA systems.
Also, inconsistencies in the literature remain regarding the mol-
ecular genetics of schizotypy. Future studies are needed to provide
firmer answers on the important question of the molecular genetic
makeup of schizotypy. Given the advance in sample sizes in the
genetics of schizophrenia and the likely small sizes of genetic effects
on schizophrenia spectrum phenotypes (201), it will be important
to substantially increase sample sizes in the study of molecular
genetic correlates of schizotypy. A promising way to achieve appro-
priate sample sizes is the establishment of multi-site collaborations
under the guidance of consortia.
An additional avenue for future work concerns the direct
comparison between individuals with high levels of schizotypy
and patients with schizophrenia. While differences between indi-
viduals with high and low schizotypy scores have been shown
on numerous occasions, much less is known about differences
between highly schizotypal individuals and schizophrenia patients.
Such a comparison would allow the identification of factors
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that perhaps protect schizotypes from developing the full-blown
clinical condition (24).
Finally, it should be pointed out as a limitation that this
overview provides merely a qualitative discussion of the evidence
of an association between DA and schizotypy. An important future
contribution to this literature would be a formal meta-analysis of
the size and significance of this association across different studies
and methods.
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